201 related articles for article (PubMed ID: 27378673)
21. Treatment of von Willebrand Disease.
Curnow J; Pasalic L; Favaloro EJ
Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
[TBL] [Abstract][Full Text] [Related]
22. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
23. Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies.
van den Biggelaar M; Bierings R; Storm G; Voorberg J; Mertens K
J Thromb Haemost; 2007 Nov; 5(11):2235-42. PubMed ID: 17958741
[TBL] [Abstract][Full Text] [Related]
24. Storage of factor VIII variants with impaired von Willebrand factor binding in Weibel-Palade bodies in endothelial cells.
van den Biggelaar M; Bouwens EA; Voorberg J; Mertens K
PLoS One; 2011; 6(8):e24163. PubMed ID: 21909383
[TBL] [Abstract][Full Text] [Related]
25. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
Ryu JH; Bauer KA; Schulman S
J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
[TBL] [Abstract][Full Text] [Related]
26. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
27. Clearance of von Willebrand factor.
Denis CV; Christophe OD; Oortwijn BD; Lenting PJ
Thromb Haemost; 2008 Feb; 99(2):271-8. PubMed ID: 18278174
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
[TBL] [Abstract][Full Text] [Related]
29. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
30. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis.
Swystun LL; Michels A; Lillicrap D
J Thromb Haemost; 2023 Aug; 21(8):2007-2019. PubMed ID: 37085036
[TBL] [Abstract][Full Text] [Related]
31. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
[TBL] [Abstract][Full Text] [Related]
33. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease.
Schwarz HP; Schlokat U; Mitterer A; Váradi K; Gritsch H; Muchitsch EM; Auer W; Pichler L; Dorner F; Turecek PL
Semin Thromb Hemost; 2002 Apr; 28(2):215-26. PubMed ID: 11992244
[TBL] [Abstract][Full Text] [Related]
34. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
35. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
36. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
[TBL] [Abstract][Full Text] [Related]
37. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
Federici AB; Mannucci PM
Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
[TBL] [Abstract][Full Text] [Related]
38. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.
Fuller JR; Knockenhauer KE; Leksa NC; Peters RT; Batchelor JD
Blood; 2021 May; 137(21):2970-2980. PubMed ID: 33569592
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
40. Analysis of current perioperative management with Haemate
Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
